Fulgent Genetics

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fulgent Genetics surpasses revenue targets, eyes precision medicine growth

Fulgent Genetics delivered strong financial performance in 2022, exceeding revenue guidance and positioning for continued growth in 2023 across key business segments.
The company's strategic focus on precision medicine, oncology, and pharma services, coupled with a robust cash position, sets the stage for future expansion and innovation.
Challenges in margin improvement and reimbursement highlight areas for operational refinement, while opportunities in acquisitions and menu expansion offer avenues for sustained growth.

Fulgent Genetics reports robust Q1 revenue growth and strategic advancements

Fulgent Genetics delivered strong revenue growth in Q1 2023, with a focus on core business strength and promising developments in key drug candidates and business segments.
While facing challenges in operational efficiency and negative Adjusted EBITDA, the company maintains a strong cash position and is optimistic about future opportunities.
Strategic acquisitions, market expansion, and continued margin improvement are key areas of focus for Fulgent Genetics to drive sustained growth and profitability.

Fulgent Genetics reports record Q2 revenue and advances in cancer treatment

Fulgent Genetics (FLGT) delivered a strong performance in Q2 2023, with record core revenue and promising developments in cancer treatment.
The company's focus on innovation, operational efficiency, and margin improvement underscores a commitment to sustainable growth.
While facing challenges in cost management and competitive dynamics, Fulgent Genetics is well-positioned to capitalize on opportunities through technology and strategic initiatives.

Fulgent Genetics reports robust Q3 earnings, eyes growth in precision diagnostics

Fulgent Genetics demonstrated solid financial performance in Q3 2023, with strong core revenue and improved gross margins. The company continues to focus on precision diagnostics and therapeutic development, presenting growth opportunities. Challenges include fluctuations in Pharma services revenue and COVID-19 testing demand.

Fulgent Genetics surpasses Q4 revenue targets, eyes FDA regulatory landscape

Fulgent Genetics delivered strong Q4 results, exceeding revenue guidance and showcasing growth in core revenue.
The company faces challenges in BioPharma Services and Anatomic Pathology but is investing in operations and AI for improvement.
Opportunities lie in Precision Diagnostics growth, market share gains in carrier screening, and adapting to FDA oversight of laboratory developed tests.
Management's confidence in quality systems and readiness to pursue FDA approval for high-risk tests position Fulgent Genetics for regulatory changes.

Fulgent Genetics excels in Q1 2024 with strong revenue growth

Fulgent Genetics delivered strong Q1 results driven by precision diagnostics and therapeutic development progress.
While facing challenges in managing expenses, the company showcased financial discipline and innovation in new product launches.
With a focus on improving margins and capturing market opportunities, Fulgent Genetics aims for continued growth and profitability in 2024.

Fulgent Genetics reports robust Q2 revenue, invests in innovative treatments

Fulgent Genetics demonstrated solid revenue performance in Q2, driven by core business growth in key segments.
While facing profitability challenges, the company continues to invest in innovative treatments and technology.
Maintaining a strong cash position and focusing on strategic growth areas position Fulgent Genetics for future success.
Balancing cost management with revenue growth will be crucial for the company's financial health and long-term sustainability.

Fulgent Genetics reports robust Q3 earnings, eyes strategic growth opportunities

Fulgent Genetics demonstrated solid revenue growth and financial stability in Q3 2024.
The company's focus on precision diagnostics and therapeutic development shows promise for future growth.
Challenges lie in maintaining margins, managing expenses, and optimizing the VA contract's impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded by Ming Hsieh on May 13, 2016 and is headquartered in El Monte, CA.

San Diego, California--(Newsfile Corp. - September 21, 2022) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fulgent Genetics, Inc. (NASDAQ: FLGT) securities between March 22, 2019 and August 4, 2022, inclusive (the "Class Period") have until November 21, 2022 to seek appointment as lead plaintiff in the Fulgent Genetics class action lawsuit. Captioned Pugley v. Fulgent Genetics, Inc., No. 22-cv-06764 (C.D. Cal.

INVESTOR DEADLINE: Fulgent Genetics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FLGT

SAN DIEGO--(BUSINESS WIRE)---- $FLGT #COVID19--The U.S. Department of Justice is Investigating Fulgent Genetics, Inc. (FLGT) for Violations of the Anti-Kickback Statute and the Stark Law

Fulgent Genetics, Inc. Investor Alert: Robbins LLP Informs Shareholders of Class Action Against Fulgent Genetics, Inc. (FLGT)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) securities between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”). Fulgent investors have until November 21, 2022 to file a lead plaintiff motion. If you suffered a loss on your Fulg

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fulgent Genetics, Inc. (FLGT) Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fulgent Genetics, Inc. (NASDAQ: FLGT) between March 22, 2019 and August 4, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than November 21, 2022. SO WHAT: If you purchased Fulgent Genetics securities during the Class Period you may be entitled to co

EQUITY ALERT: Rosen Law Firm Encourages Fulgent Genetics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FLGT

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) securities between March 22, 2019 and August 4, 2022, inclusive (the “Class Period”). Fulgent investors have until November 21, 2022 to file a lead plaintiff motion. Investors suffering losses on their Fulgent investments are encouraged to contact the Law Offices of Howard G. Sm

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fulgent Genetics, Inc. (FLGT) Investors

Atlanta, Georgia--(Newsfile Corp. - September 21, 2022) - Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Fulgent Genetics, Inc. ("Fulgent Genetics" or the "Company") (NASDAQ: FLGT).

SHAREHOLDER ALERT: Holzer & Holzer Announces a Class Action Was Filed on Behalf of Fulgent Genetics (FLGT) Investors and Encourages Investors With Significant Losses to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--NHorstman@rgrdlaw.com,bpulido@rgrdlaw.com,AFinizio@rgrdlaw.com,JanetS@rgrdlaw.com

INVESTOR ALERT: Fulgent Genetics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Fulgent Genetics Class Action Lawsuit - FLGT

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fulgent To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 20, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT).If you suffered losses exceeding $50,000 investing in Fulgent stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Fulgent Investor Alert

New York, New York--(Newsfile Corp. - September 1, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (""Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Fulgent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

Los Angeles, California--(Newsfile Corp. - August 12, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ: FLGT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Fulgent Genetics, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 11, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ: FLGT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Fulgent Genetics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $FLGT #classaction--The law firm of Kirby McInerney LLP is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). The investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices. Fulgent engages in the provision of gene testing and sequencing solutions. The Company offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling sol

Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Fulgent Genetics, Inc. (FLGT)

Los Angeles, California--(Newsfile Corp. - August 10, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ: FLGT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Fulgent Genetics, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 9, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ: FLGT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Fulgent Genetics, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of Fulgent stockholders. Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Fulgent released its financial results for the second quarter of

FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Fulgent investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Fulgent Genetics, Inc. (FLGT) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) investors concerning the Company's possible violations of federal securities laws. On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC is conducting an investigation into certain Exchange Act reports for 2018 through the first quarter of 2020. This comes after the Company recei

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fulgent Genetics, Inc. (FLGT) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC is conducting an investigation into certain Exchange Act reports fo

The Law Offices of Frank R. Cruz Announces Investigation of Fulgent Genetics, Inc. (FLGT) on Behalf of Investors

This healthcare business has tailwinds behind it.

Why I Bought More of This Under-the-Radar Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2022 Results Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Nicole Borsje - Investor Relations, The Blueshirt Group Ming Hsieh - Chairman and Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Lawrence Weiss - Chief Medical Officer Paul Kim - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Operator Good day and welcome to the Q2 2022 Fulgent Genetics Earnings Conference Call. As reminder, today's call is being recorded.

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q2 2022 Results - Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (FLGT) Q2 Earnings and Revenues Beat Estimates

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2022. Second Quarter 2022 Results: Revenue of $125.3 million, versus $153.6 million in Q2 2021 Billable tests delivered over 1.3 million, versus 1.6 mil

Fulgent Genetics Reports Second Quarter 2022 Financial Results

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced it has launched a test for monkeypox that leverages the U.S. Centers for Disease Control and Prevention's (CDC) orthopoxvirus test, which detects non-smallpox related orthopoxviruses, including monkeypox. Ful

Fulgent Genetics Announces Launch of PCR Based Test to Detect Monkeypox

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of two therapeutic industry veterans to its board of directors. Dr. Michael Nohaile, Chief Scientific Officer of Generate Biomedicines (“Generate”), and Dr. Leonard Post, Chief Scientific Officer of Vivace Therapeutics (“Vivace”), who joined the company's Board of Directors, effective August 1, 2022. “We are pleased and honored to welcome Dr.

Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 4, 2022. The company's Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, Chief C

News for Fulgent Genetics Stock (FLGT)